- 收听数
- 0
- 听众数
- 7
- 最后登录
- 2024-11-8
- QQ
- UID
- 9301
- 阅读权限
- 10
- 帖子
- 1189
- 精华
- 0
- 在线时间
- 380 小时
- 注册时间
- 2014-5-1
- 科研币
- 2
- 速递币
- 21
- 娱乐币
- 1794
- 文献值
- 0
- 资源值
- 0
- 贡献值
- 0
|
5速递币
题名 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | 链接 | http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)60845-X.pdf |
|
|